Table 2.
Characteristics of 11 patients with severe COVID-19 pneumonia and B cell loss or B cell preservation in the bone marrow or spleen.
| Characteristics of the COVID-19 cohort (n = 11) | Severe B cell loss (n = 7) | B cell preservation (n = 4) |
|---|---|---|
| Pulmonary SARS-CoV-2 RNA level, log10 copies/ml, median (IQR) | 2.46 (1.73–5.90) | 2.69 (1.49–3.64) |
| Age, years, median (IQR) | 71 (68–79) | 65 (61–76) |
| Time to death, days, median (95% CI) | 19 (6–32) | 19 (16–22) |
| Number of comorbidities, median (IQR) | 4 (3–5) | 5 (5–5) |
| Viral co-infection, n (%) | 1 (14) | 1 (25) |
| Bacterial co-infection, n (%) | 3 (43) | 3 (75) |
| Fungal co-infection, n (%) | 1 (14) | 1 (25) |
| HIV, n (%) | 1 (14) | 0 (0) |
| Autoimmune disease, n (%) | 0 (0) | 1 (25) |
| History of solid malignancy, n (%) | 2 (30) | 0 (0) |
| ICU (invasive ventilation, ECMO, HD), n (%) | 6 (86) | 3 (75) |
| Sepsis, n (%) | 5 (71) | 3 (75) |
| Pulmonary abscesses, autopsy proof, n (%) | 2 (30) | 1 (25) |
| ARDS with autopsy proof of DAD, n (%) | 5 (71) | 4 (100) |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; log, logarithm; RNA, ribonucleic acid; n, number of patients; IQR, interquartile range; CI, confidence interval; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; HD, haemodialysis; ARDS, acute respiratory distress syndrome.